The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Nefazodona     2-[3-[4-(3- chlorophenyl)piperazin-1...

Synonyms: nefazodone, Nefazodonum, Nefazodone Hcl, CHEMBL623, SureCN35089, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07256


Psychiatry related information on C07256


High impact information on C07256


Chemical compound and disease context of C07256


Biological context of C07256

  • Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis [13].
  • Although nefazodone may interact with some other medications (e.g., increases at steady state in AUC: alprazolam, twofold; triazolam, fourfold), drug-drug interactions involving patients have been clinically minor [15].
  • Our knowledge of the isoenzymes involved in the various oxidation pathways and their relevance for potential drug interactions varies from a considerable amount for most of the SSRI and nefazodone, to minimal for reboxetine and tianeptine [16].
  • Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20% [17].
  • We examined retrospective data from our clinic to investigate whether nefazodone has utility in the treatment of nonparaphilic compulsive sexual behavior [18].

Anatomical context of C07256


Associations of C07256 with other chemical compounds

  • These differential sleep EEG effects are consistent with the notion that nefazodone and fluoxetine may have somewhat different modes and spectra of action [8].
  • The results of the study demonstrated that the decrease from mean baseline platelet 5-HT after SSRI treatment was significantly greater than the change after nefazodone treatment (-88% vs. -3%; Mann-Whitney U-test, p = 0.0002) [24].
  • Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression [25].
  • A range of effective pharmacotherapeutic strategies are available, including tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, the 5-HT2 blocker nefazodone, and the serotonin-norepinephrine reuptake inhibitor venlafaxine [26].
  • It was later shown to inhibit both serotonin and norepinephrine uptake in vitro, attributes which most likely impart its clinical efficacy and which differentiate nefazodone from its chemical predecessor trazodone [27].

Gene context of C07256


Analytical, diagnostic and therapeutic context of C07256

  • The effects of a novel antidepressant, nefazodone (50 mg, 100 mg, and 200 mg orally) on neuroendocrine function and temperature were assessed using a single-blind, crossover design in eight healthy male volunteers [31].
  • To determine if differences exist among the newer antidepressants, the authors retrospectively analyzed data from clinical trials comparing nefazodone with SSRIs and with imipramine [32].
  • Pharmacotherapy consisted of open-label nefazodone, 300-600 mg per day in two divided doses prescribed by psychiatrists [33].
  • This double-blind study tested the efficacy of nefazodone versus placebo for the treatment of depression in actively drinking alcohol-dependent patients who were also participating in weekly group treatment for alcoholism [34].
  • CONCLUSION: Results from this preliminary retrospective study suggest that nefazodone decreases the frequency of sexual obsessions and compulsions but does not produce the undesired sexual side effects caused by SSRI treatment [18].


  1. Nefazodone-induced liver failure: report of three cases. Aranda-Michel, J., Koehler, A., Bejarano, P.A., Poulos, J.E., Luxon, B.A., Khan, C.M., Ee, L.C., Balistreri, W.F., Weber, F.L. Ann. Intern. Med. (1999) [Pubmed]
  2. Nefazodone-induced carbamazepine toxicity. Ashton, A.K., Wolin, R.E. The American journal of psychiatry. (1996) [Pubmed]
  3. Contemporary management of depression. Andrews, J.M., Nemeroff, C.B. Am. J. Med. (1994) [Pubmed]
  4. Treatment of chronic fatigue syndrome with nefazodone. Goodnick, P.J., Jorge, C.M. The American journal of psychiatry. (1999) [Pubmed]
  5. Nefazodone-induced hypoglycemia in a diabetic patient with major depression. Warnock, J.K., Biggs, F. The American journal of psychiatry. (1997) [Pubmed]
  6. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. Keller, M.B., McCullough, J.P., Klein, D.N., Arnow, B., Dunner, D.L., Gelenberg, A.J., Markowitz, J.C., Nemeroff, C.B., Russell, J.M., Thase, M.E., Trivedi, M.H., Zajecka, J. N. Engl. J. Med. (2000) [Pubmed]
  7. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Hirschfeld, R.M., Dunner, D.L., Keitner, G., Klein, D.N., Koran, L.M., Kornstein, S.G., Markowitz, J.C., Miller, I., Nemeroff, C.B., Ninan, P.T., Rush, A.J., Schatzberg, A.F., Thase, M.E., Trivedi, M.H., Borian, F.E., Crits-Christoph, P., Keller, M.B. Biol. Psychiatry (2002) [Pubmed]
  8. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Rush, A.J., Armitage, R., Gillin, J.C., Yonkers, K.A., Winokur, A., Moldofsky, H., Vogel, G.W., Kaplita, S.B., Fleming, J.B., Montplaisir, J., Erman, M.K., Albala, B.J., McQuade, R.D. Biol. Psychiatry (1998) [Pubmed]
  9. Nefazodone and akathisia. Eberstein, S., Adler, L.A., Angrist, B. Biol. Psychiatry (1996) [Pubmed]
  10. Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. Davis, L.L., Nugent, A.L., Murray, J., Kramer, G.L., Petty, F. Journal of clinical psychopharmacology. (2000) [Pubmed]
  11. Rhabdomyolysis with simvastatin and nefazodone. Thompson, M., Samuels, S. The American journal of psychiatry. (2002) [Pubmed]
  12. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Abernethy, D.R., Barbey, J.T., Franc, J., Brown, K.S., Feirrera, I., Ford, N., Salazar, D.E. Clin. Pharmacol. Ther. (2001) [Pubmed]
  13. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Barbhaiya, R.H., Shukla, U.A., Natarajan, C.S., Behr, D.A., Greene, D.S., Sainati, S.M. Clin. Pharmacol. Ther. (1995) [Pubmed]
  14. Effect of pharmacologic treatments on the sleep of depressed patients. Sharpley, A.L., Cowen, P.J. Biol. Psychiatry (1995) [Pubmed]
  15. The safety profile of nefazodone. Robinson, D.S., Roberts, D.L., Smith, J.M., Stringfellow, J.C., Kaplita, S.B., Seminara, J.A., Marcus, R.N. The Journal of clinical psychiatry. (1996) [Pubmed]
  16. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Caccia, S. Clinical pharmacokinetics. (1998) [Pubmed]
  17. Clinical pharmacokinetics of nefazodone. Greene, D.S., Barbhaiya, R.H. Clinical pharmacokinetics. (1997) [Pubmed]
  18. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. Coleman, E., Gratzer, T., Nesvacil, L., Raymond, N.C. The Journal of clinical psychiatry. (2000) [Pubmed]
  19. Nefazodone in the breast milk of nursing mothers: a report of two patients. Dodd, S., Maguire, K.P., Burrows, G.D., Norman, T.R. Journal of clinical psychopharmacology. (2000) [Pubmed]
  20. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. von Moltke, L.L., Greenblatt, D.J., Granda, B.W., Grassi, J.M., Schmider, J., Harmatz, J.S., Shader, R.I. Psychopharmacology (Berl.) (1999) [Pubmed]
  21. Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain. Ortega-Alvaro, A., Acebes, I., Saracíbar, G., Echevarría, E., Casis, L., Micó, J.A. Psychopharmacology (Berl.) (2004) [Pubmed]
  22. Effects of nefazodone on the immune system of mice. Freire-Garabal, M., Varela, M., Riveiro, P., Balboa, J., Liñares, D., Mañá, P., Mayán, J.M., Rey-Méndez, M., Núñez, M.J. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (2000) [Pubmed]
  23. Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Marathe, P.H., Salazar, D.E., Greene, D.S., Brennan, J., Shukla, U.A., Barbhaiya, R.H. Pharm. Res. (1995) [Pubmed]
  24. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. Narayan, M., Anderson, G., Cellar, J., Mallison, R.T., Price, L.H., Nelson, J.C. Journal of clinical psychopharmacology. (1998) [Pubmed]
  25. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Hicks, J.A., Argyropoulos, S.V., Rich, A.S., Nash, J.R., Bell, C.J., Edwards, C., Nutt, D.J., Wilson, S.J. The British journal of psychiatry : the journal of mental science. (2002) [Pubmed]
  26. The patient with comorbid depression and anxiety: the unmet need. Bakish, D. The Journal of clinical psychiatry. (1999) [Pubmed]
  27. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Taylor, D.P., Carter, R.B., Eison, A.S., Mullins, U.L., Smith, H.L., Torrente, J.R., Wright, R.N., Yocca, F.D. The Journal of clinical psychiatry. (1995) [Pubmed]
  28. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Owen, J.R., Nemeroff, C.B. Depression and anxiety. (1998) [Pubmed]
  29. The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Haduch, A., Wójcikowski, J., Daniel, W.A. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (2006) [Pubmed]
  30. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Millan, M.J. Thérapie. (2005) [Pubmed]
  31. Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Walsh, A.E., Hockney, R.A., Campling, G., Cowen, P.J. Biol. Psychiatry (1993) [Pubmed]
  32. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. Sussman, N., Ginsberg, D.L., Bikoff, J. The Journal of clinical psychiatry. (2001) [Pubmed]
  33. The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Manber, R., Rush, A.J., Thase, M.E., Amow, B., Klein, D., Trivedi, M.H., Korenstein, S.G., Markowitz, J.C., Dunner, D.L., Munsaka, M., Borian, F.E., Martin, n.u.l.l., Keller, B. Sleep. (2003) [Pubmed]
  34. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. Roy-Byrne, P.P., Pages, K.P., Russo, J.E., Jaffe, C., Blume, A.W., Kingsley, E., Cowley, D.S., Ries, R.K. Journal of clinical psychopharmacology. (2000) [Pubmed]
WikiGenes - Universities